Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Executive Officer | January 21, 2021 | January 25, 2021 |
| Origin Materials, Inc.ORGN · Entity 52695 | CFO and COO | March 04, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date January 21, 2021 · Filed January 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,285 |
Reported balance
After 2020-08-03 transaction · row 1
1 source rowRow 1 · 2020-08-03 · Purchase · Acquired 585 · Balance 14,285 F1: Reflects the purchase of 585 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.05 · Expires 2031-01-21 | Direct | 435,450 |
Reported balance
After 2021-01-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-21 · Grant · Acquired 250,000 · Balance 435,450 F2: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the purchase of 585 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan.
F2: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service.
Origin Materials, Inc.
Report date March 04, 2026 · Filed April 13, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,340,231 |
Reported balance
After 2026-03-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-04 · Grant · Acquired 32,000 · Balance 1,340,231 F1: Reporting Person earned 32,000 shares upon the satisfaction of the performance condition of certain performance stock units granted to the Reporting Person on February 26, 2025. The performance conditions were deemed to have been 40% achieved on March 4, 2026. One-third of these stock units vested as of March 4, 2026, one-third will vest on January 1, 2027 and one-third will vest on January 1, 2028, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person earned 32,000 shares upon the satisfaction of the performance condition of certain performance stock units granted to the Reporting Person on February 26, 2025. The performance conditions were deemed to have been 40% achieved on March 4, 2026. One-third of these stock units vested as of March 4, 2026, one-third will vest on January 1, 2027 and one-third will vest on January 1, 2028, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 21:32 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001326765-26-000003 · form4-03052026_090348.xml · derivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-03-04 F1 · derivative.exercise_date: Fifty percent (50%) of the option vests on February 17, 2027 and fifty percent (50%) of the option vests on February 17, 2028, so long as the Reporting Person continues to provide services through such vesting dates. Read SEC document |
| March 04, 2026 Filed Apr 13, 2026 20:41 UTC Amendment | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001326765-26-000004 · form4a-04132026_080425.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,340,231 F1 · shares: Reporting Person earned 32,000 shares upon the satisfaction of the performance condition of certain performance stock units granted to the Reporting Person on February 26, 2025. The performance conditions were deemed to have been 40% achieved on March 4, 2026. One-third of these stock units vested as of March 4, 2026, one-third will vest on January 1, 2027 and one-third will vest on January 1, 2028, subject to the Reporting Person's continued service. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 21:03 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 12,000 | $0.20 | $2,392.80 |
DisclosureSEC source: 0001326765-26-000002 · form4-01202026_090111.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308,231 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.1993 to $0.2001. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 23:04 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 40,000 | $0.21 | $8,384.00 |
DisclosureSEC source: 0001326765-25-000007 · form4-12292025_111245.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,320,231 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.2088 to $0.213. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 01:46 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 150,000 | $0.55 | $82,500.00 |
DisclosureSEC source: 0001326765-25-000006 · form4-11052025_011154.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,360,231 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.5450 to $0.5785. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 9,725 | $0.86 | $8,343.08 |
DisclosureSEC source: 0001415889-25-007367 · form4-03072025_040303.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,510,231 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.8575 to $0.8588. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:05 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 80,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005989 · form4-02282025_040203.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,519,956 F1 · shares: Reporting Person earned 80,368 shares upon the satisfaction of the performance condition of certain performance stock units granted to the Reporting Person on December 26, 2023. One-third of these stock units vested as of February 26, 2025, one-third will vest on January 1, 2026 and one-third will vest on January 1, 2027, subject to the Reporting Person's continued service. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:15 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 24,500 | $1.02 | $25,110.05 |
DisclosureSEC source: 0001415889-24-030315 · form4-12312024_041207.xml · nonDerivative · entry 2 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,439,588 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person (pursuant to a 10b5-1 Plan dated September 13, 2024) to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $1.015 to $1.035. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2024 Filed Dec 31, 2024 21:15 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 241,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030315 · form4-12312024_041207.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · CFO and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,464,088 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 23, 2024, provided that Reporting Person continues to provide services to the Company through each vesting date. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 23:52 UTC | Origin Materials, Inc. ORGN · Entity 52695 | SaleCommon Stock | 120,000 | $1.32 | $157,860.00 |
DisclosureSEC source: 0001415889-24-026277 · form4-11062024_111144.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223,088 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $1.29 to $1.35. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:21 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 241,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059899 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,343,088 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of December 26, 2023, provided that Reporting Person continues to provide services to the Company through each vesting date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:47 UTC | Origin Materials, Inc. ORGN · Entity 52695 | GrantCommon Stock | 1,101,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054030 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101,983 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of October 30, 2023, provided that Reporting Person continues to provide services to the Company through each vesting date. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 23:51 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-005219 · doc4.xml · derivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,450 Underlying: Common Stock · 250,000 shares Expires 2031-01-21 F2 · derivative.exercise_date: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service. Read SEC document |
| August 03, 2020 Filed Jan 25, 2021 23:51 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 585 | $3.16 | $1,848.60 |
DisclosureSEC source: 0001209191-21-005219 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,285 F1 · shares: Reflects the purchase of 585 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 76,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-20-006282 · doc4.xml · derivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,450 Underlying: Common Stock · 76,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The option vests in 48 equal installments beginning February 29, 2020 and ending January 31, 2024. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $1.72 | $1,204.00 |
DisclosureSEC source: 0001209191-20-006282 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · shares: Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/20 at a per share purchase price of $1.72 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 18:32 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon stock | 1,000 | $4.08 | $4,079.50 |
DisclosureSEC source: 0001209191-19-056884 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| September 23, 2019 Filed Sep 23, 2019 23:18 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 2,000 | $5.25 | $10,500.00 |
DisclosureSEC source: 0001209191-19-050493 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| September 10, 2019 Filed Sep 10, 2019 22:24 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $6.52 | $6,520.50 |
DisclosureSEC source: 0001209191-19-049077 · doc4.xml · nonDerivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| September 10, 2019 Filed Sep 10, 2019 22:24 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $6.49 | $6,493.00 |
DisclosureSEC source: 0001209191-19-049077 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| August 28, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $6.88 | $6,880.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 7 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| August 28, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $6.88 | $6,880.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 7 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 2,000 | $8.93 | $17,860.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 6 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $8.95 | $8,950.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 5 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $9.30 | $9,300.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 4 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $9.32 | $9,320.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 3 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 2,000 | $8.93 | $17,860.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 6 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $8.95 | $8,950.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 5 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $9.30 | $9,300.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 4 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| August 27, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $9.32 | $9,320.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 3 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $9.22 | $9,220.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 17:01 UTC Amendment | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 1,000 | $8.33 | $8,330.00 |
DisclosureSEC source: 0001209191-19-047582 · doc4a.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $9.22 | $9,220.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 14:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock | 1,000 | $8.33 | $8,330.00 |
DisclosureSEC source: 0001209191-19-047580 · doc4.xml · nonDerivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| June 03, 2019 Filed Jun 7, 2019 20:00 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-035500 · doc4.xml · derivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,450 Underlying: Common Stock · 26,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option vests with respect to 25% of the total securities subject to the option on the first anniversary of the date of award, or June 3, 2020, with the remaining 75% vesting in 36 equal installments beginning June 30, 2020 and ending May 31, 2023, subject to the Participant's continued service. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 23:24 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 47,200 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-051840 · doc4.xml · derivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,450 Underlying: Common Stock · 47,200 shares Expires 2028-09-18 F1 · derivative.exercise_date: The options will vest monthly in equal installments over a period of two years from the date of the grant, subject to the Participant's continued service. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 22:07 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-17-038975 · doc4.xml · derivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-06-08 F1 · shares: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 21:29 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140964 · doc4.xml · derivative · entry 5 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2026-09-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 21:29 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140964 · doc4.xml · derivative · entry 4 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2026-09-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 21:29 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140964 · doc4.xml · derivative · entry 3 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-09-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 21:29 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140964 · doc4.xml · derivative · entry 2 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-09-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 21:29 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001209191-16-140964 · doc4.xml · derivative · entry 1 Plavan Matthew T · CIK 0001326765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2026-09-11 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on 9/12/2017; the remaining 75% of the total number of shares subject to the option will vest in 36 equal installments, with the first installment occurring 9/30/2017, and thereafter on the last day of the month for the next 35 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.